Afatinib Dimaleate - CAS 850140-73-7
Catalog number: B0084-463336
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C32H33ClFN5O11
Molecular Weight:
717.18
COA:
Inquire
Targets:
EGFR
Description:
Afatinib Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-463336 500 mg $198 In stock
Bulk Inquiry
Purity:
>98%
MSDS:
Inquire
InChIKey:
USNRYVNRPYXCSP-JUGPPOIOSA-N
InChI:
InChI=1S/C24H25ClFN5O3.2C4H4O4/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15;2*5-3(6)1-2-4(7)8/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29);2*1-2H,(H,5,6)(H,7,8)/b4-3+;2*2-1-/t16-;;/m0../s1
Canonical SMILES:
CN(C)CC=CC(=O)NC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC(=C(C=C3)F)Cl)OC4CCOC4.C(=CC(=O)O)C(=O)O.C(=CC(=O)O)C(=O)O
1.The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.
Liu CY;Wang CL;Li SH;Hsu PC;Chen CH;Lin TY;Kuo CH;Fang YF;Ko HW;Yu CT;Yang TY;Yang CT Oncotarget. 2017 Jun 27;8(57):97602-97612. doi: 10.18632/oncotarget.18746. eCollection 2017 Nov 14.
The choice of a first-line therapy for lung cancer is a crucial decision that can impact the survival as well as the quality of life of a patient. Inhibitors of epidermal growth factor receptor (EGFR) such as afatinib, erlotinib, and gefitinib have previously been used to treat non-small cell lung cancer harboring favorable EGFR mutations. Although afatinib has greater efficacy than other EGFR inhibitors, adverse events related to its use can result in the discontinuation of the therapy. In this study, we compared the therapeutic efficacy in lung cancer patients of a regimen of 40 mg/day of afatinib with that of a lower dose regimen of <40 mg/day resulting either from a lower starting dose of 30 mg/day or dose adjustment. Seventy-nine patients were treated with 40 mg/day and 67 received de-escalated doses of <40 mg/day. There was no significant difference in the clinical characteristics of the two groups except that the proportion of patients with a body weight of 50 kg or more was greater in the 40 mg/day group. Otherwise, there were no significant differences between the two groups in the average time to treatment failure (TTF), the rates at which the administration of a second-line therapy was necessary, or the frequency and severity of adverse events.
2.Next generation tyrosine kinase inhibitor (TKI): afatinib.
Kumar S;Agrawal R Recent Pat Anticancer Drug Discov. 2014;9(3):382-93.
Afatinib is a recently introduced new tyrosine kinase inhibitor, approved by the USFDA on July 12, 2013. Afatinib is marketed under the trade name Gilotrif and developed by Boehringer Ingelheim GmbH. It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations. Afatinib is a covalent, irreversible inhibitor of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2) and HER4. Chemically afatinib is a 4-anilinoquinazoline derivative, having an acrylamide warhead. Gilotrif is the formulation of Afatinib di-meleate salt. Presently, afatinib has been approved in the USA, the European Union, Taiwan and Mexico. In this review, we have summarized the chemical characterization of afatinib, its synthesis, patent status, marketed formulation, available crystalline form and current clinical trials.
3.Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
Keating GM Drugs. 2014 Feb;74(2):207-21. doi: 10.1007/s40265-013-0170-8.
Afatinib (Gilotrif™, Giotrif(®)) is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases. Afatinib downregulates ErbB signalling by covalently binding to the kinase domains of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, resulting in irreversible inhibition of tyrosine kinase autophosphorylation; it also inhibits transphosphorylation of HER3. Afatinib is approved as monotherapy for the treatment of EGFR tyrosine kinase inhibitor (TKI)-naïve adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutations in the EU, and for the first-line treatment of patients with metastatic NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test in the US. In two randomized, open-label, multinational phase III trials, progression-free survival was significantly prolonged with afatinib compared with pemetrexed plus cisplatin (LUX-Lung 3) or gemcitabine plus cisplatin (LUX-Lung 6) in treatment-naïve patients with advanced NSCLC with activating EGFR mutations. The objective response rate was significantly higher with afatinib than with pemetrexed plus cisplatin or gemcitabine plus cisplatin, and patient-reported outcomes for symptoms such as cough and dyspnoea and certain health-related quality of life measures significantly favoured afatinib versus pemetrexed plus cisplatin or gemcitabine plus cisplatin.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related EGFR Products


CAS 1626387-80-1 AZD3759

AZD3759
(CAS: 1626387-80-1)

AZD3759 is a n orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity. Upon oral administration, AZD3...

BGB-283
(CAS: 1446090-77-2)

BGB-283 is a selective Epidermal growth factor receptor and Proto oncogene protein b raf inhibitor under the development of BeiGene. BGB-283 shows antitumor act...

CAS 937263-43-9 Irbinitinib

Irbinitinib
(CAS: 937263-43-9)

Irbinitinib,also known as ARRY-380 and ONT-380, is an orally bioavailable inhibitor of the human epidermal growth factor receptor tyrosine kinase ErbB-2 (also...

BMS 599626 dihydrochloride

BMS 599626 dihydrochloride is a potent and selective EGFR and ErbB2 inhibitor (IC50 = 22 nM and 32 nM, respectively), and also inhibits HER4 (IC50 = 190 nM). BM...

EGFR-IN-2
(CAS: 1643497-70-4)

EGFR-IN-2 is a a noncovalent, irreversible, mutant-selective second generation EGFR inhibitor. It showed excellent cellular activity against both the single and...

CAS 881001-19-0 HDS 029

HDS 029
(CAS: 881001-19-0)

HDS 029 is a potent inhibitor of the ErbB receptor family including EGFR, ErbB2 and ErbB4 (IC50 = 0.3, 0.5 and 1.1 nM for ErbB1 (EGFR), ErbB4 and ErbB2, respect...

CAS 1216920-18-1 BIBX 1382 dihydrochloride

BIBX 1382 dihydrochloride
(CAS: 1216920-18-1)

BIBX 1382 dihydrochloride is a potent and selective inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 3 nM) with > 1000-fold lower po...

CAS 171179-06-9 PD158780

PD158780
(CAS: 171179-06-9)

PD158780 is a potent, cell-permeable, reversible ATP-competitive inhibitor of EGFR tyrosine kinase activity with IC50 values of 0.008, 49 and 52 nM for EGFR, Er...

Chemical Structure

CAS 850140-73-7 Afatinib Dimaleate

Quick Inquiry

Verification code

Featured Items